• According to estimates, One in Three People Who Have Type 2 Diabetes Also Have Chronic Kidney Disease.
  • Both Chronic Conditions Are Associated with an Increased Risk of Stroke and Heart Attack.
  • A New Study has found a medication already used to treat pele -who has type 2 diabetes and/or chronic Kidney Disease with Added Heart Disease Risks Also Helps Lower their Stroke and Heart Attack Risk.

Researchers Estimate That As Many As 840 Million People Globally Live With Chronic Kidney Disease – A Disease That Steadily Damages The Kidneys, Leading to Function Loss.

Another Estimated 828 Million People Around the World Have Diabetes, which is when their body does not use or make insulin properly. Up to 95% OF PEOPLE WITH DIABETES HAVE TYPE 2 DIABETES.

While these are two separate chronic conditions, they are linked as aBout One In Every Three Adults With Type 2 Diabetes Also has chronic Kidney Disease.

Additionionally, Both Conditions Are Associated with an Increased Risk for Cardiovascular Complications Such As Stroke and Heart Attack.

Now, New Study Recently Published in the Journal The Lancet Diabetes & EndocrinologyYou have found that at US FDA-Approved Medication Already Used To Treat People Who Have Type 2 Diabetes and Chronic Kidney Disease with Added Heart Disease Risks Also Helps Lower Their Stroke and Heart Attack Risk.

Focusing on Sotagliflozin

This Study Analyzed Data from the Scored Trial, which was a multicenter Clinical Trial Including Study participants Who Had Type 2 Diabetes, Chronic Kidney Disease, and Heart Disease Risks. Participants in the Study Received Eithher A Placebo or A Medication Called Sotagliflozin.

“The Scored Trial Examined Patients with Diabetes, Kidney Disease, and Additional Cardiovascular Risks, Because of the Known High Rate of Cardiac Problems Weake The Dr. Valentin Fuster PROFESSOR OF CARDIOVASCULAR MEDICINE AT THE ICAHN SCHOOL OF MEDICINE AT MOUT SINAI, AND LEAD AUTHOR OF THIS STUDY TOLED Medical News Today.

“We saw a signant benefit in therms of feWer Heart Failure and Adverse Kidney Events. We Wanted to see if Heart Attack and Stroke Risks Might Also Be reduced, ”He Said.

“(Sotagliflozin) is a drarug that blocks a receiver in the Kidneys, street sglt2 (sodium-glucose Cotransporter 2), leading to glucose elimination in the urine, Among Many Additional Effects,” Bhatt Added. “OTHER Popular Medications Such As Pagliflozin And Dapagliflozin Also Block This Receiver.”

23% Heart Attack, Stroke Risk Reduction with Sotagliflozin

For This Study, Bhatt and His Team Analyzed Data from Almost 10,600 Scored Trial Participants Who Received Eithher Sotagliflozin Or A Between Between 2017 to 2020 and were Follow Fuck for About 16 Months.

UPON ANALYSIS, FOUND THAT REFOCHERS TKING TAKING SOTAGLIFLOZIN LOWERED ESIR RISK OF HART ATTACK, STROKE, AND DEATH FROM Cardiovascular Causes By 23% Combase to Those Taking the Placebo.

“The Benefit Oscurred Within Just Three Months of Starting the Drug, Which is … Remarkable to see Such an Early Effect in a Stable, Outpatient Population,” Bhatt Said. “Examined Separately, There was at 32% Reduction in Heart Attack and 34% Reduction in Stroke.”

“People with Diabetes and Kidney Disease Are at Vry High Risk of Cardiovascular Complications, Such as Heart Attack and Stroke,” I have added. “We need new therapies to help reduces these risks.”

Inhibiting SGLT1 + SGLT2 RECEPORS MAY BE THE KEY

WHEN ASKED how Sotagliflozin Might Help Lower Heart Attack and Stroke Risk, Bhatt Said It May Be Baser The Drug Also Blocks The Sgg1 (Sodium-Glucose Cotransporter 1) As Well receiver.

“This receiver is Found in the Kidneys, Gut, Heart, and Brain,” I explained. “We are additional sites of action May Explain Why Sotagliflozin Reduces The Risk of Both Heart Attack and Stroke, and Those Othher Drugs Do Not.”

“In Patients with Diabetes, Kidney Disease, and Additional Cardiovascular Risk Factors, Combined Inhibition of the SGLT2 and SGLT1 Receivers by Sotagliflozin Reduces The Risk of Heart Failure, Kidney Disease Progression, Heart Attacks, and Strokes. This multi-pronged approach could lead to a substantial reduction in cardiovascular risk in choosing patients who are treated with This medication. ”
– Deepak L. Bhatt, MD, MPH, MBA

When Asked About the Next Steps for This Research, Bhatt Said That Sotagliflozin Should Be Studied in Other Populations at High Risk for Heart Attack and Stroke.

“Those would to Be Large, Long-Trials Trials, So We Would To Find Sumone To Fund Such Research,” I have continued. “In the Meantime, Smaller Basic Science Experiments Are Ongoing to examine the Biological Actions of Blocking Sglt1 Receptors That May Explain Sotagliflozin’s Unique Ability (Among the Sgg inhibitor Class of Drugs) to reduce Heart Attack and Stroke Risk.”

Helping Improve The Lives of High Risk Patients

MNT Also Had the Opportunity To Speak with Michael Broukhim, MD, A Board Certified Insteentional Cardiologist at Providence Saint John’s Health Center in Santa Monica, CA, About This Study.

“SGLT2 Inhibitors have scholarship an important part of our treatment of patients with heart failure,” Brukhim Said. “If Sotagliflozin you have the added benefit of reduction in myocardial infarcation and stroke, we May wish to use this agent more to treat high risk patients.”

“People with Type 2 Diabetes or Kidney Disease have significantly elevated risks for heart attack and stroke despite ort available treatments. If we have additional agents that can reduce Risks of Heart and Stroke, That Will Help Us Improve The Lives of First High-Risk Patients. ”
– Michael Broukhim, MD

“I woould like to see more data differentiating the actions of a sglt2 inhibitor and an agent that inhibits that Patient Populations Will Benefit More from One particular agent over the other, ”Brukhim Added.